Herbert Loong

24PUBLICATIONS
180CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Jun 01, 2026
Tumor-Agnostic Therapies: Translating Scientific Breakthroughs Into Global Implementation.

|Apr 24, 2026
In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors.

|Apr 09, 2026
Why are we still using cisplatin? : Rationale for the continued use of cisplatin in oncology.

Jemma Arakelyan, Herbert Loong, Robert Peter Gale

|Jan 15, 2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.

Sarah Waliany, Alissa J Cooper, Stephen V Liu

|Oct 17, 2025
Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.

Xiuning Le, Tae Min Kim, Herbert H Loong

|Oct 15, 2025
Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer.

Franziska Siegel, Stephan Siegel, Kristýna Kotýnková

Pageof 4

Frequent Collaborators

5 joint publications

Vivek Subbiah

4 joint publications

Alexander Drilon

3 joint publications

Koichi Goto

3 joint publications

Chun Sing Lam